Last edition
News about "Razel (Rosuvastatin)"
JB Pharma to acquire the entire Razel (Rosuvastatin) franchise for Rs. 314 crores
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy. Razel ranks among the top 10 brands in the Rosuvastatin molecule category in the country <br />
Razel (Rosuvastatin) | 15/12/2022 | By Sudeep Soparkar | 389
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members